Trefoil Therapeutics

Trefoil Therapeutics is a private, clinical-stage biotech founded in 2012 and based in San Diego, focused on first-in-class treatments for corneal diseases. Its core asset is TTHX1114, an engineered, stabilized form of FGF1, which is being advanced in two distinct programs: an intracameral injection for endothelial conditions like Fuchs Endothelial Corneal Dystrophy (FECD) and a topical eye drop for epithelial damage. The company has raised $45 million in venture financing, secured non-dilutive funding from the NIH and DoD, and has reported positive Phase 2 data for its endothelial program, positioning it to address a significant unmet need in ophthalmology with a novel regenerative approach.

Engineered, stabilized form of Fibroblast Growth Factor 1 (FGF1) designed for pharmaceutical use to stimulate endogenous corneal cell regeneration.

Competition includes other biotechs developing pharmacological treatments for corneal healing, advanced surgical techniques like DSO (without an adjunct drug), and tissue-engineered corneal grafts. Trefoil's differentiation lies in its engineered FGF1 platform targeting endogenous regeneration, potentially offering a less invasive and more accessible alternative to transplantation.